Author details

Full Name

John F de Groot

Affiliation

ORCID

Career Start Year

2004

Papers

192

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36723868	An expedited strategy for accurate and timely integrated molecular diagnosis ofÂ gliomas.	Neuro Oncol	2023
35657335	Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.	Neuro Oncol	2023
37584601	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.	Cancer Discov	2023
37774317	RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.	J Clin Oncol	2023
36765553	Preclinical Models of Low-Grade Gliomas.		2023
37200018	External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma.		2023
36617262	Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.	Neuro Oncol	2023
37114244	Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience.	Neurooncol Adv	2023
36990614	Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.	Lancet Oncol	2023
37509400	The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.	Cancers (Basel)	2023
37488293	Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.	Nat Med	2023
35101778	Clinical and survival characteristics of primary and secondary gliosarcoma patients.	Clin Neurol Neurosurg	2022
35575067	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.	CNS Oncol	2022
35945463	Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.	Acta Neuropathol	2022
36128585	Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis.	Neurooncol Adv	2022
35611270	Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastoma.	Neurooncol Adv	2022
34990326	Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists.	Radiographics	2022
35179134	Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.	Neurosurgery	2022
34756799	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma.	Hematol Oncol Clin North Am	2022
34999836	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.	Neuro Oncol	2022
34693288	Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.	Neurooncol Adv	2021
32112296	Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors.	J Neurooncol	2021
33738447	The promise of DNA damage response inhibitors for the treatment of glioblastoma.	Neurooncol Adv	2021
34146775	IDH mutation status and the development of venous thromboembolism in astrocytoma patients.	Journal of the Neurological Sciences	2021
34031054	Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models.	Clin Cancer Res	2021
33822177	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.	Neuro Oncol	2021
34337411	Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.	Neurooncol Adv	2021
34244484	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.	Nat Commun	2021
33647972	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.	Neuro Oncol	2021
33199490	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.	Clin Cancer Res	2021
32750703	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.	Neuro Oncol	2021
33433610	PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.	Neuro Oncol	2021
34972978	Neurologic Toxicities of Immunotherapy.	Advances in Experimental Medicine and Biology	2021
34972967	Immunotherapy for Neuro-oncology.	Advances in Experimental Medicine and Biology	2021
34771447	Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells.	Cancers (Basel)	2021
34377989	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.	Neurooncol Adv	2021
34755486	Aggressiveness of care at end of life in patients with high-grade glioma.	Cancer Medicine	2021
32605912	Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.	Clin Cancer Res	2020
31852834	<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.	Clin Cancer Res	2020
31900480	Exclusion of patients with brain metastases from cancer clinical trials.	Neuro Oncol	2020
32182988	Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance.	International Journal of Molecular Sciences	2020
31786276	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.	Int J Radiat Oncol Biol Phys	2020
31679017	Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.	Neuro Oncol	2020
32301015	Immunotherapy for Neuro-Oncology.	Advances in Experimental Medicine and Biology	2020
32299815	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.	Clin Cancer Res	2020
32296828	Potential neurologic and oncologic implications of the novel coronavirus.	Neuro-Oncology	2020
31873309	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.	Nat Med	2020
32154928	NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.	Cancer	2020
31982279	Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma.	Journal of Clinical Neuroscience	2020
31755915	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.	Neuro Oncol	2020